3-alkyl-(5,5'-diphenyl)imidazolidinediones as new cannabinoid receptor ligands

Bioorganic and Medicinal Chemistry Letters

Volumn 9, Issue 15, 1999, Pages 2233-2236

  Kanyonyo, Martial ^a   Govaerts, Sophie J ^a   Hermans, Emmanuel ^a   Poupaert, Jacques H ^a   Lambert, Didier M ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [6 METHOXY 2 (4 METHOXYPHENYL) 3 BENZOFURANYLCARBONYL]BENZONITRILE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; CANNABINOID RECEPTOR; DEXANABINOL; IMIDAZOLIDINE DERIVATIVE; JWH 030; LIGAND; RIMONABANT; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING KINETICS; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN;

ANIMALS; CANNABINOIDS; CHO CELLS; CRICETINAE; HUMANS; IMIDAZOLES; LIGANDS; PIPERIDINES; PYRAZOLES; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION;

ANIMALIA;

EID: 0033517063     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(99)00353-4     Document Type: Article

References (14)

1. For review, Pertwee, R.G. Pharmacol. Ther. 1997, 74, 129.
2. Shire, D.; Carillon, C.; Kaghad, M.; Calandra, B.; Rinaldi-Carmona, M.; Le Fur, G.; Caput, D.; Ferrara, P. J. Biol. Chem. 1995, 270, 3726.
3. Barth, F. Exp. Opin. Ther. Patents 1998, 8, 301.
4. Rinaldi-Carmona, M.; Barth, F.; Héaulme, M.; Shire, D.; Calandra, B.; Congy C.; Martinez S.; Maruani, J.; Néliat, G.; Caput, D.; Ferrara, P.; Soubrié, P.; Brelière, J.C.; Le Fur, G. FEBS Lett. 1994, 350, 240.
5. Rinaldi-Carmona, M.; Barth, F.; Millan, J.; Derocq, J.M.; Casellas, P.; Congy, C.; Oustric, D.; Sarran, M.; Bouaboula, M.; Calandra, B.; Portier, M.; Shire, D.; Brelière, J.C.; Le Fur, G. J. Pharmacol. Exp. Ther. 1998, 284, 644.
6. Felder, C.C.; Joyce, K.E.; Briley, E.M.; Glass, M.; Mackie, K.P.; Fahey, K.J.; Cullinan, G.J.; Hunden, D.C.; Johnson, D.W.; Chaney, M.O.; Koppel, G.A.; Brownstein, M. J. Pharmacol. Exp. Ther. 1998, 254, 291.
7. Landsman, R.S.; Makriyannis, A.; Deng, H.; Consroe, P.; Roeske, W.R.; Yamamura, H.I. Life Sci. 1998, 62, PL109.
8. Lainton, J.A.H.; Huffman, J.W.; Martin, B.R.; Compton D.R., Tetrahedron Lett. 1995, 36, 1401.
9. Huffman, J.W.; Lainton, J.A.H. Curr. Med. Chem. 1996, 3, 101.
10. Willey, J.L.; Compton, D.R.; Dai, D.; Lainton, J.A.H.; Phillips M.; Huffman, J.W.; Martin, B.R. J. Pharm. Exp. Ther. 1998, 285, 995.
11. Gérard, C.M.; Mollereau, C.; Vassart, G.; Parmentier, M. Biochem J. 1991, 279, 129.
12. 2, 1 mM EDTA Na, 0.5 % fatty acid free albumin, pH 7.4) and then filtrated through Macherey Nagel MN-2 filters (pre-treated with polyethyleneimine 0.5 %(w/v). Non-specific binding was determined with 10 μM of CP 55940. Specific binding was around 75 % in these conditions.
13. Thomas, B.F.; Gilliam, A.F.; Burch D.F.; Roche, M.J.; Seltzman, H.H. J. Pharmacol. Exp. Ther. 1998, 285, 285.
14. Bouaboula, M.; Perrachon, S.; Michigan, L.; Canat, X.; Rinaldi-Carmona, M.; Portier, M.; Barth, F.; Calandra, B.; Pecceu, F.; Lupker, J.; Maffrand, J.P.; Casellas, P. J. Biol. Chem. 1997, 272, 22330.